Evidence map›Paper›PMID 38755333›Full record

ArticleScientific reports2024

A method for delivering the required neutron fluence in an accelerator-based boron neutron capture therapy system employing a lithium target.

Satoshi Nakamura, Mihiro Takemori, Tetsu Nakaichi, Yasunori Shuto, Tairo Kashihara, Kotaro Iijima, Takahito Chiba, Hiroki Nakayama, Yuka Urago, Shuka Nishina and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Satoshi NakamuraDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. satonaka@ncc.go.jp.
Mihiro TakemoriDivision of Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research and Clinical Trial Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Tetsu NakaichiDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yasunori ShutoDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Tairo KashiharaDivision of Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research and Clinical Trial Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kotaro IijimaDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takahito ChibaDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroki NakayamaDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yuka UragoDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shuka NishinaDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yuta KobayashiDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hironori KishidaDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shoji ImamichiDivision of Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research and Clinical Trial Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kana TakahashiDepartment of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Mitsuko MasutaniDivision of Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research and Clinical Trial Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiroyuki OkamotoDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Teiji NishioMedical Physics Laboratory, Division of Health Science, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita City, Osaka, 565-0871, Japan.
Jun ItamiRadiation Therapy, Shin-Matsudo Central General Hospital, 1-380 Shin-Matsudo, Matsudo City, Chiba, 270-0034, Japan.
Hiroshi IgakiDivision of Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research and Clinical Trial Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

Japan Agency for Medical Research and Development 23mk0121267h0001Japan Society for the Promotion of Science 19K17218
6 · The paper itself

Abstract

Accelerator-based boron neutron capture therapy (BNCT) systems employing a solid-state lithium target indicated the reduction of neutron flux over the lifetime of a target, and its reduction could represent the neutron flux model. This study proposes a novel compensatory approach for delivering the required neutron fluence and validates its clinical applicability. The proposed approach relies on the neutron flux model and the cumulative sum of real-time measurements of proton charges. The accuracy of delivering the required neutron fluence for BNCT using the proposed approach was examined in five Li targets. With the proposed approach, the required neutron fluence could be delivered within 3.0%, and within 1.0% in most cases. However, those without using the proposed approach exceeded 3.0% in some cases. The proposed approach can consider the neutron flux reduction adequately and decrease the effect of uncertainty in neutron measurements. Therefore, the proposed approach can improve the accuracy of delivering the required fluence for BNCT even if a neutron flux reduction is expected during treatment and over the lifetime of the Li target. Additionally, by adequately revising the approach, it may apply to other type of BNCT systems employing a Li target, furthering research in this direction.

Indexed as

Boron Neutron Capture TherapyLithiumNeutronsHumansParticle AcceleratorsRadiotherapy DosageLithiumAccelerator-based BNCTBoron neutron capture therapy (BNCT)Li targetNeutron fluence

Identifiers

PMID38755333
PMCPMC11099010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.